Benzinga  Sep 30  Comment 
Verastem, Inc. (NASDAQ: VSTM) shares closed at $1.75 yesterday, down slightly after a day where the stock lost 67% of it value. Investors of Verastem, Inc. may want to gain valuable insight by reading or due diligence. Get our report at the...
Benzinga  Sep 29  Comment 
Analysts at Scotia Howard Weil downgraded Williams Companies Inc (NYSE: WMB) to Sector Perform. Williams Companies shares closed at $36.57 on Monday. Analysts at Mizuho Securities downgraded Verastem Inc (NASDAQ: VSTM) from Buy to Neutral. The...
Forbes  Sep 28  Comment 
In trading on Monday, drugs shares were relative laggards, down on the day by about 8.3%. Helping drag down the group were shares of Verastem (VSTM), down about 72.5% and shares of Epizyme (EPZM) down about 29.5% on the day.
Benzinga  Sep 28  Comment 
Verastem Inc (NASDAQ: VSTM) shares dipped 60.67 percent to $2.23 after the company reported stopping enrollment in COMMAND study of VS-6063. Huntsman Corporation (NYSE: HUN) shares declined 16.89 percent to $11.56. On Friday, Huntsman identified...
FierceBiotech  Sep 28  Comment 
A little more than a month ago Verastem had to mount a hasty defense of its lead drug defactinib (VS-6063) after an abstract hit the Twittersphere outlining poor efficacy and serious adverse events in its study for non-small cell lung cancer. This...
FierceBiotech  Aug 26  Comment 
Shares of Verastem cratered Wednesday morning as the Twitter crowd passed around an abstract on the company's defactinib (VS-6063), highlighting an extremely poor response rate for KRAS mutant non-small cell lung cancer.
Benzinga  Aug 26  Comment 
Schlumberger Limited. (NYSE: SLB) shares fell 4.44 percent to touch a new 52-week low of $69.29 after the company announced its plans to acquire Cameron International Corporation (NYSE: CAM) in a $14.8 billion deal. Verastem Inc (NASDAQ: VSTM)...
Benzinga  Aug 26  Comment 
Verastem Inc (NASDAQ: VSTM) shares dropped 14.28 percent to $5.67 after rising 2.16 percent on Tuesday. Republic Airways Holdings Inc. (NASDAQ: RJET) shares declined 12.24 percent to $2.94 after rising 5.02 percent on Tuesday. Seabridge...


Verastem (NASDAQ:VSTM) is a biopharmaceutical company which is developing small moleculre drugs to target cancer stem cells. The company believes that cancer stem cells are a key reason to the recurrence of tumors. These cells are resistant to chemotherapy and other cancer therapies. Verastem's drug will use small molecule compounds to directly target these cancer stem cells. [1]

Business Overview

Verastem is a prerevenue company. For the nine months ended in September of 2011, the company reported a net loss of $8M.[2]

New Updates

The company's initial public offering of stock on the NASDAQ occurred on January 26, 2012. The company offered 5.5M shares each for $10. This was within the $9-$11 initial price range. The deal raised a total of $55M. The lead mangers of the deal were UBS and Leerink Swann.[3]

Trends & Forces

A Prerevenue R&D

At the time of its IPO, Verastem was early in its drug development stage. As a result, the company will have to successfully discover, receive approval, and commercialize a drug based on the money it has. If it fails to do that, it will have to find some other way to generate a cash flow. Because a drug like the one Verastem plans to discover has never been commercialized it is unclear if it is possible or if the FDA would approve it.[4]

  1. VSTM S-1/A 2011 PROSPECTUS SUMMARY "Overiew" pg.1-2
  2. VSTM S-1/A 2011 PROSPECTUS SUMMARY "Selected financial data" pg.48
  3. Renaissance Capital - IPO Home "Verastem prices upsized IPO at $10 midpoint" Jan 26 2012
  4. VSTM S-1/A 2011 PROSPECTUS SUMMARY "Risk factors" pg.11
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki